Total Payments
$11,810
2024 Payments
$1,945
Companies
67
Transactions
674
Medicare Patients
3,120
Medicare Billing
$417,741
Payment Breakdown by Category
Food & Beverage$11,385 (96.4%)
Education$424.65 (3.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,385 | 663 | 96.4% |
| Education | $424.65 | 11 | 3.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,223 | 72 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $888.87 | 66 | $0 (2024) |
| PFIZER INC. | $793.63 | 46 | $0 (2024) |
| Janssen Biotech, Inc. | $694.54 | 36 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $693.17 | 48 | $0 (2024) |
| Merck Sharp & Dohme LLC | $617.80 | 35 | $0 (2024) |
| Lilly USA, LLC | $609.07 | 32 | $0 (2024) |
| Celgene Corporation | $519.01 | 28 | $0 (2024) |
| Amgen Inc. | $518.67 | 34 | $0 (2023) |
| Incyte Corporation | $430.51 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,945 | 98 | Genentech USA, Inc. ($151.13) |
| 2023 | $2,323 | 118 | Seagen Inc. ($195.26) |
| 2022 | $2,511 | 124 | Janssen Biotech, Inc. ($382.82) |
| 2021 | $520.17 | 29 | Novartis Pharmaceuticals Corporation ($93.87) |
| 2020 | $391.41 | 26 | Novartis Pharmaceuticals Corporation ($55.95) |
| 2019 | $1,676 | 110 | Novartis Pharmaceuticals Corporation ($188.94) |
| 2018 | $1,169 | 80 | Novartis Pharmaceuticals Corporation ($236.58) |
| 2017 | $1,274 | 89 | Novartis Pharmaceuticals Corporation ($226.17) |
All Payment Transactions
674 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $28.86 | General |
| Category: Hematology/Oncology | ||||||
| 12/16/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $18.78 | General |
| Category: Oncology | ||||||
| 12/12/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $19.73 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $18.64 | General |
| Category: Oncology | ||||||
| 12/02/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $29.61 | General |
| Category: Oncology | ||||||
| 11/14/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Apellis Pharmaceuticals, Inc. | Empaveli (Drug) | Food and Beverage | In-kind items and services | $25.10 | General |
| Category: Hematology | ||||||
| 11/04/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $32.86 | General |
| Category: Oncology | ||||||
| 11/01/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: BioOncology | ||||||
| 10/31/2024 | Ipsen Biopharmaceuticals, Inc | Onivyde (Drug) | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Genentech USA, Inc. | Tecentriq (Biological) | Food and Beverage | In-kind items and services | $10.46 | General |
| Category: BioOncology | ||||||
| 10/24/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $29.73 | General |
| Category: ONCOLOGY | ||||||
| 10/17/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: HEMATOLOGY | ||||||
| 10/15/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $15.29 | General |
| Category: Oncology | ||||||
| 10/10/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $27.53 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $28.95 | General |
| Category: Hematology | ||||||
| 10/03/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $19.91 | General |
| Category: ONCOLOGY | ||||||
| 09/25/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $19.18 | General |
| Category: Hematology | ||||||
| 09/23/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.80 | General |
| Category: ONCOLOGY | ||||||
| 09/16/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $25.66 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $19.24 | General |
| Category: ONCOLOGY | ||||||
| 09/11/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: Oncology | ||||||
| 09/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.80 | General |
| 09/05/2024 | PFIZER INC. | XTANDI (Drug) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 582 | 1,338 | $444,240 | $106,660 |
| 2022 | 11 | 603 | 1,246 | $388,546 | $97,809 |
| 2021 | 10 | 934 | 1,959 | $198,780 | $101,019 |
| 2020 | 15 | 1,001 | 2,878 | $252,297 | $112,254 |
Total Patients
3,120
Total Services
7,421
Medicare Billing
$417,741
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 116 | 455 | $197,725 | $45,165 | 22.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 174 | 380 | $117,715 | $26,343 | 22.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 63 | 222 | $40,930 | $13,163 | 32.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 55 | 55 | $29,425 | $7,331 | 24.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 47 | 51 | $16,830 | $5,076 | 30.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 27 | 27 | $12,960 | $3,292 | 25.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 57 | 79 | $17,315 | $3,156 | 18.2% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 32 | 58 | $6,885 | $2,202 | 32.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 11 | 11 | $4,455 | $933.17 | 20.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 110 | 277 | $117,505 | $29,728 | 25.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 173 | 432 | $131,440 | $29,212 | 22.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 57 | 212 | $36,820 | $11,260 | 30.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 65 | 65 | $34,345 | $8,715 | 25.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 40 | 40 | $19,200 | $6,109 | 31.8% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 36 | 40 | $13,200 | $4,068 | 30.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 47 | 59 | $12,865 | $2,580 | 20.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 21 | 31 | $7,550 | $2,450 | 32.5% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 31 | 67 | $6,315 | $1,913 | 30.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 12 | 12 | $4,860 | $1,156 | 23.8% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2022 | 11 | 11 | $4,446 | $617.22 | 13.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 140 | 258 | $39,990 | $22,680 | 56.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 69 | 150 | $30,750 | $18,502 | 60.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 119 | 191 | $29,605 | $14,526 | 49.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 53 | 99 | $20,295 | $11,154 | 55.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 32 | 110 | $11,550 | $6,008 | 52.0% |
About Dr. Krishnamohan Basarakodu, MD
Dr. Krishnamohan Basarakodu, MD is a Hematology & Oncology healthcare provider based in Dothan, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1235248477.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Krishnamohan Basarakodu, MD has received a total of $11,810 in payments from pharmaceutical and medical device companies, with $1,945 received in 2024. These payments were reported across 674 transactions from 67 companies. The most common payment nature is "Food and Beverage" ($11,385).
As a Medicare-enrolled provider, Basarakodu has provided services to 3,120 Medicare beneficiaries, totaling 7,421 services with total Medicare billing of $417,741. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Dothan, AL
- Active Since 08/30/2006
- Last Updated 04/25/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1235248477
Products in Payments
- OPDIVO (Biological) $622.00
- KEYTRUDA (Biological) $571.27
- LIBTAYO (Biological) $317.26
- IBRANCE (Drug) $311.38
- DARZALEX (Biological) $289.86
- CYRAMZA (Drug) $285.77
- VERZENIO (Drug) $255.53
- REBLOZYL (Biological) $255.42
- KISQALI (Drug) $249.82
- JAKAFI (Drug) $219.80
- TAGRISSO (Drug) $212.38
- TASIGNA (Drug) $209.09
- Pomalyst (Drug) $179.67
- XTANDI (Drug) $177.46
- BOSULIF (Drug) $167.72
- PROMACTA (Drug) $166.76
- Cabometyx (Drug) $152.53
- AFINITOR (Drug) $152.35
- Neulasta (Biological) $148.64
- ERLEADA (Drug) $136.68
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Dothan
Dr. Michael Mcallister, M.d, M.D
Hematology & Oncology — Payments: $57,549
Hematology & Oncology $57,549
Dr. John Dunn, M.d, M.D
Hematology & Oncology — Payments: $23,253
Hematology & Oncology $23,253
Dr. Jawaunna Blackmon, M.d, M.D
Hematology & Oncology — Payments: $10,135
Hematology & Oncology $10,135
Dr. Thuy-Hong Le-Kumar, Md, MD
Hematology & Oncology — Payments: $736.87
Hematology & Oncology $736.87
Ramaseetha Gutta, M.d, M.D
Hematology & Oncology
Hematology & Oncology
Dr. Rafael Mayor, M.d, M.D
Hematology & Oncology
Hematology & Oncology